127 related articles for article (PubMed ID: 2785092)
1. Clinical trial with clofazimine for treating erythema dyschromicum perstans. Evaluation of cell-mediated immunity.
Piquero-Martín J; Pérez-Alfonzo R; Abrusci V; Briceño L; Gross A; Mosca W; Tapia F; Convit J
Int J Dermatol; 1989 Apr; 28(3):198-200. PubMed ID: 2785092
[TBL] [Abstract][Full Text] [Related]
2. Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy.
Baranda L; Torres-Alvarez B; Cortes-Franco R; Moncada B; Portales-Perez DP; Gonzalez-Amaro R
Arch Dermatol; 1997 Mar; 133(3):325-9. PubMed ID: 9080892
[TBL] [Abstract][Full Text] [Related]
3. Erythema dyschromicum perstans: response to dapsone therapy.
Bahadir S; Cobanoglu U; Cimsit G; Yayli S; Alpay K
Int J Dermatol; 2004 Mar; 43(3):220-2. PubMed ID: 15009398
[TBL] [Abstract][Full Text] [Related]
4. Successful Management of Erythema Dyschromicum Perstans Following Topical Ruxolitinib Therapy.
Srinivasan D; Gottlieb A
J Drugs Dermatol; 2023 Mar; 22(3):297-299. PubMed ID: 36877872
[TBL] [Abstract][Full Text] [Related]
5. Mononuclear cell subpopulations and infiltrating lymphocytes in erythema dyschromicum perstans and vitiligo.
Gross A; Tapia FJ; Mosca W; Perez RM; Briceño L; Henriquez JJ; Convit J
Histol Histopathol; 1987 Jul; 2(3):277-83. PubMed ID: 2980730
[TBL] [Abstract][Full Text] [Related]
6. Erythema Dyschromicum Perstans: Response to Topical Tacrolimus.
Mahajan VK; Chauhan PS; Mehta KS; Sharma AL
Indian J Dermatol; 2015; 60(5):525. PubMed ID: 26538750
[TBL] [Abstract][Full Text] [Related]
7. Immunopathologic study of erythema dyschromicum perstans (ashy dermatosis).
Vásquez-Ochoa LA; Isaza-Guzmán DM; Orozco-Mora B; Restrepo-Molina R; Trujillo-Perez J; Tapia FJ
Int J Dermatol; 2006 Aug; 45(8):937-41. PubMed ID: 16911378
[TBL] [Abstract][Full Text] [Related]
8. Erythema dyschromicum perstans. Immunopathologic studies.
Miyagawa S; Komatsu M; Okuchi T; Shirai T; Sakamoto K
J Am Acad Dermatol; 1989 May; 20(5 Pt 2):882-6. PubMed ID: 2785541
[TBL] [Abstract][Full Text] [Related]
9. Erythema dyschromicum perstans and lichen planus.
Naidorf KF; Cohen SR
Arch Dermatol; 1982 Sep; 118(9):683-5. PubMed ID: 7114873
[TBL] [Abstract][Full Text] [Related]
10. Clinical and histological aspect of erythema dyschromicum perstans in Korea: A review of 68 cases.
Chang SE; Kim HW; Shin JM; Lee JH; Na JI; Roh MR; Lee JH; Lee GY; Ko JY
J Dermatol; 2015 Nov; 42(11):1053-7. PubMed ID: 26118942
[TBL] [Abstract][Full Text] [Related]
11. Erythema dyschromicum perstans: a case report and review.
Osswald SS; Proffer LH; Sartori CR
Cutis; 2001 Jul; 68(1):25-8. PubMed ID: 11480143
[TBL] [Abstract][Full Text] [Related]
12. Improvement of erythema dyschromicum perstans using a combination of the 1,550-nm erbium-doped fractionated laser and topical tacrolimus ointment.
Wolfshohl JA; Geddes ER; Stout AB; Friedman PM
Lasers Surg Med; 2017 Jan; 49(1):60-62. PubMed ID: 27552666
[TBL] [Abstract][Full Text] [Related]
13. Erythema dyschromicum perstans.
Tschen JA; Tschen EA; McGavran MH
J Am Acad Dermatol; 1980 Apr; 2(4):295-302. PubMed ID: 6767758
[TBL] [Abstract][Full Text] [Related]
14. Erythema elevatum diutinum.
Farella V; Lotti T; Difonzo EM; Panconesi EX
Int J Dermatol; 1994 Sep; 33(9):638-40. PubMed ID: 8002161
[No Abstract] [Full Text] [Related]
15. Erythema dyschromicum perstans and vitiligo.
Naik NS
Dermatol Online J; 2003 Oct; 9(4):25. PubMed ID: 14594598
[TBL] [Abstract][Full Text] [Related]
16. Periorbital hyperpigmentation and erythema dyschromicum perstans.
Ing EB; Buncic JR; Weiser BA; de Nanassy J; Boxall L
Can J Ophthalmol; 1992 Dec; 27(7):353-5. PubMed ID: 1490247
[TBL] [Abstract][Full Text] [Related]
17. Controlled long-term therapy of leprosy with B663 (lamprene, clofazimine) compared with DDS.
Tolentino JG; Rodriquez JN; Abalos RM
Int J Lepr Other Mycobact Dis; 1974; 42(4):416-418. PubMed ID: 4617720
[No Abstract] [Full Text] [Related]
18. Erythema dyschromicum perstans: A case report and systematic review of histologic presentation and treatment.
Leung N; Oliveira M; Selim MA; McKinley-Grant L; Lesesky E
Int J Womens Dermatol; 2018 Dec; 4(4):216-222. PubMed ID: 30627620
[TBL] [Abstract][Full Text] [Related]
19. [Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy].
Rodríguez G; Pinto R; López F; Gómez Y
Biomedica; 2009 Mar; 29(1):18-24. PubMed ID: 19753835
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial with clofazimine in leprosy.
Ganapati R; Dongre VV
Lepr India; 1976 Oct; 48(4 Suppl):703-8. PubMed ID: 1026807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
